CCL22 and CCL17 cancer biomarkers

Patent metadata

Field	Value
Publication number	US-10241118-B2
Application number	US-201414782929-A
Country	US
Kind code	B2
Filing date	Apr 9, 2014
Priority date	Apr 9, 2013
Publication date	Mar 26, 2019
Grant date	Mar 26, 2019

Abstract

The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.

First claim

The invention claimed is:

1. A method of diagnosing and treating cancer in a patient, said method comprising:
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio;
e) diagnosing said patient with cancer if said ratio is increased; and
f) administering an effective amount of an anti-CCR4 treatment to said diagnosed patient, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and(ii) a chemical CCR4 antagonist.

2. A method according to claim 1 , wherein said method involves determining the levels of CCL17 and CCL22 using antibodies.

3. A method according to claim 1 , wherein said cancer is a carcinoma.

4. A method according to claim 1 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

5. A method of monitoring the progression of cancer and treating said cancer in a patient, said method comprising:
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio;
e) determining that said cancer has progressed if said ratio is increased; and
f) administering an effective amount of an anti-CCR4 treatment to said patient whose cancer has progressed, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and(ii) a chemical CCR4 antagonist.

6. A method according to claim 5 , wherein said method involves determining the levels of CCL17 and CCL22 using antibodies.

7. A method according to claim 5 , wherein said cancer is a carcinoma.

8. A method according to claim 5 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

9. A method of making a prognosis of cancer and treating said cancer in a patient, said method comprising:
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio;
e) determining that said patient has an adverse cancer prognosis if said ratio is increased; and
f) administering an effective amount of an anti-CCR4 treatment to said patient with an adverse cancer prognosis, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and (ii) a chemical CCR4 antagonist.

10. A method according to claim 9 , wherein said method involves determining the levels of CCL17 and CCL22 using antibodies.

11. A method according to claim 9 , wherein said cancer is a carcinoma.

12. A method according to claim 9 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

13. A method of predicting the response of a cancer to an anti-CCR4 treatment and treating said cancer in a patient, said method comprising:
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio;
e) determining that said cancer has an increased likelihood of responding to said treatment if said ratio is increased; and
f) administering an effective amount of an anti-CCR4 treatment to said patient having a cancer with an increased likelihood of responding to said treatment, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and(ii) a chemical CCR4 antagonist.

14. A method according to claim 13 , wherein said method involves determining the levels of CCL17 and CCL22 using antibodies.

15. A method according to claim 13 , wherein said cancer is a carcinoma.

16. A method according to claim 13 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

17. A method of treating a cancer in a patient, said method comprising administering an effective amount of an anti-CCR4 treatment to said patient, wherein said patient was previously diagnosed with having cancer, having a poor cancer prognosis, or having a cancer that has progressed, based on a method comprising
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio; and
e) diagnosing said patient with having cancer, having a poor cancer prognosis, or having a cancer that has progressed, if said ratio is increased, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and(ii) a chemical CCR4 antagonist.

18. A method according to claim 17 , wherein said cancer is a carcinoma.

19. A method according to claim 17 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

20. A method of treating a cancer in a patient, said method comprising administering an effective amount of an anti-CCR4 treatment to said patient, wherein said cancer was previously predicted to have an increased likelihood of responding to an anti-cancer treatment based on a method comprising
a) measuring the level of CCL17 in a blood, plasma or serum sample from said patient;
b) measuring the level of CCL22 in a blood, plasma or serum sample from said patient;
c) determining the ratio of said CCL17 level to said CCL22 level;
d) comparing said determined ratio to a control or reference ratio; and
e) predicting that said cancer has an increased likelihood of responding to an anti-cancer treatment if said ratio is increased, wherein said anti-CCR4 treatment is selected from the group consisting of (i) an antibody which binds directly to CCR4, CCL17 or CCL22, and(ii) a chemical CCR4 antagonist.

21. A method according to claim 20 , wherein said method involves measuring the levels of CCL17 and CCL22 using antibodies.

22. A method according to claim 20 , wherein said cancer is a carcinoma.

23. A method according to claim 20 , wherein said cancer is selected from renal cancer, ovarian cancer and pancreatic cancer.

Assignees

• Cancer Research Tech Ltd
• Cancer Research Tech Ltd

Inventors

• Balkwill Frances
• Berlato Chiara
• Fletcher Laura

Classifications

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• G01N2333/523

  Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2 · CPC title

• G01N33/68 Primary

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• C07K16/24

  against cytokines, lymphokines or interferons · CPC title

• A61P35/00

  Antineoplastic agents · CPC title